HUTCHMED (CHINA) LIMIT

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

28 11 2024 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

21 11 2024 22:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 

20 11 2024 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

05 11 2024 22:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

31 10 2024 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

15 10 2024 23:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

24 9 2024 02:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

08 9 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

29 8 2024 23:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

21 8 2024 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

31 7 2024 06:00:01 提供 Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

03 7 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED to Announce 2024 Half-Year Financial Results

26 6 2024 03:30:00 提供 Nasdaq GlobeNewswire

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

24 6 2024 04:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

21 6 2024 15:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

16 6 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

06 6 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

02 6 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

23 5 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

17 5 2024 09:00:00 提供 Nasdaq GlobeNewswire